HOOPER, LUNDY & BOOKMAN, P.C. for BRAINFUTURES
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, issues related to medical adoption of psychedelic drugs and therapies, issues related to equitable access to psychedelic drugs and therapies; S. 689/H.R. 1393, A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN New | SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996) |
Medical/Disease Research/Clinical Labs MED
Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies, issues related to medical adoption of psychedelic drugs and therapies, issues related to equitable access to psychedelic drugs and therapies; S. 689/H.R. 1393, A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes, all provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN New | SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.